Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn’s disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose–response trial

INTRODUCTION: The medical treatment options for patients with Crohn’s disease (CD) are limited and patients resistant to those therapies are left requiring surgical operations that usually only achieve some symptomatic relief. Mesenchymal stem cells (MSC) have been shown to be effective for the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Otagiri, Shinsuke, Ohnishi, Shunsuke, Miura, Arisa, Hayashi, Hiroshi, Kumagai, Izumi, Ito, Yoichi M, Katsurada, Takehiko, Nakamura, Shiro, Okamoto, Rika, Yamahara, Kenichi, Cho, Kyu Yong, Isoe, Toshiyuki, Sato, Norihiro, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001910/
https://www.ncbi.nlm.nih.gov/pubmed/29915666
http://dx.doi.org/10.1136/bmjgast-2018-000206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001910/
https://www.ncbi.nlm.nih.gov/pubmed/29915666
http://dx.doi.org/10.1136/bmjgast-2018-000206

Ejemplares similares